Verastem (VSTM) Short term Debt (2018 - 2024)

Verastem (VSTM) recorded quarterly Short term Debt of $9.9 million in Q3 2024, up 100.37% quarter-over-quarter from $4.9 million in Q2 2024.

Verastem (VSTM) Short term Debt (2018 - 2024) Analysis & Trends

Verastem's Short term Debt history runs 4 years deep, the most recent figure standing at $9.9 million for Q3 2024.

In Q3 2024, Short term Debt changed N/A year-over-year to $9.9 million; the TTM figure through Sep 2024 stood at $9.9 million (changed N/A YoY), while the FY2019 annual figure was $450000.0, down 92.13% from the prior year.
Short term Debt was $9.9 million for Q3 2024 at Verastem, up from $4.9 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $9.9 million in Q3 2024 to a low of $4.6 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Verastem	407.42 Mn	225.74 Mn	15.90 Mn

Download Data